Last Price
12.25
Today's Change
+0.49 (4.16%)
Day's Change
11.79 - 12.32
Trading Volume
133,031
Market Cap
Shares Outstanding
Avg Volume
Avg Price (50 Days)
Avg Price (200 Days)
PE Ratio
EPS
Earnings Announcement
Previous Close
Open
Day's Range
Year Range
Trading Volume
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49